Clinical trials: HbA1c
Ischemic Foot Ulcer
Intensive Insulin Treatment and Ischemic Foot Ulcer
We aim to investigate the relationship between skin microvascular function and the first hospitalization for ischemic foot ulcer in patients with type 1 diabetes former randomized during 7.5 years to intensified conventional…
- Trial name
- NCT01957930
- Testing
- Intensified insulin treatment, Standard treatment
- Where
- 2 sites in Sweden
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 2
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea…
- Trial name
- NCT01106625
- Testing
- Canagliflozin, Metformin, Sulphonylruea
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 469 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes
Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics
The purpose of this study is to determine the impact of two-way short message service (SMS) on glycemic control in low-income, poorly-controlled adult diabetic patients.
- Trial name
- SAMI (NCT02049359)
- Testing
- Texting
- Where
- 3 sites in United States
- Volunteers
- 170 people
- Sponsor
- Campbell University, Incorporated
Diabetes Mellitus
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs).
- Trial name
- NCT00348374
- Testing
- Insulin Lispro, Exubera
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 191 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes
HbA1c is widely used as the gold standard for evaluating glycemic control. However, in patients who need adjusting hypoglycemic regimen, A1c was not a sensitive marker.
- Trial name
- NCT05227677
- Testing
- GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Type 2 Diabetes Mellitus, Hyperglycemia
MedStar Health Type 2 Diabetes Pathway to Control
A Diabetes Institute (MDI), in partnership with key stakeholders-including Primary Care Providers- in a northeastern US regional, mixed-payer healthcare system), seeks to implement an evidence-based, technology-enabled…
- Trial name
- T2DMBC (NCT02925312)
- Testing
- Diabetes Pathway
- Where
- United States
- Volunteers
- 419 people
- Sponsor
- Medstar Health Research Institute
Type 2 Diabetes
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
- Trial name
- NCT00614939
- Testing
- Saxagliptin
- Where
- 74 sites in United States, Belarus and 12 more
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Diabetes, Type 1, Diabetes, Type 2
The Relationship of Hemoglobin A1c and Diabetic Wound Healing
The purpose of this study is to investigate the relationship of hemoglobin A1c in diabetic wound healing. Additionally, a comparison of two wound dressings, AmeriGel® (Amerx Health Care Corp., Clearwater, FL) and Bacitracin, with…
- Conditions
- Diabetes, Type 1, Diabetes, Type 2, Foot Ulcer, Diabetic
- Trial name
- NCT01350102
- Testing
- Bacitracin, AmeriGel®, Vitamin C
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Susan Hassenbein
Diabetes Mellitus, Type 2
A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02390050
- Testing
- Bexagliflozin tablets
- Where
- 50 sites in United States, Japan
- Volunteers
- 292 people
- Sponsor
- Theracos
Diabetes Mellitus, Type 2, Obesity
CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs.
- Trial name
- NCT02912455
- Testing
- canagliflozin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Hypertension
Effects of Use of a Connected Pillbox On Medication Adherence
Medication adherence is defined as the extent to which a patient takes his or her medication as prescribed by their healthcare provider.
- Conditions
- Diabetes Mellitus, Hypertension, Hyperlipidemia
- Trial name
- (TVHST2DM) (NCT02593032)
- Testing
- Pre-filled trays
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Diabetes Mellitus, Type 2
An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (ie…
- Trial name
- NCT01340664
- Testing
- Canagliflozin 50 mg, Canagliflozin 150 mg, Metformin
- Where
- 61 sites in United States, Canada and 5 more
- Volunteers
- 279 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 (an SGLT2 inhibitor) compared to placebo, administered over 12 weeks in treatment-naive subjects with type 2 diabetes…
- Trial name
- NCT00495469
- Testing
- GSK189075
- Where
- 157 sites in United States, Canada and 14 more
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Treated With Insulin
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains…
- Trial name
- In-FI (NCT04460326)
- Testing
- Insulin glargine, NovoLog, Insulin Fiasp
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Boston Medical Center
Type2Diabetes, Diabetes
QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes.
Glycemic control is often the main indicator of successful diabetes care, but a singular focus on glycemic control may lead to patients' overall health and wellbeing being overlooked or undervalued.
- Trial name
- NCT05553912
- Testing
- QBSafe
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Yale University
Type 2 Diabetes, Hyperglycemia Due to Type 2 Diabetes Mellitus
CGM Use in Children With Type 2 Diabetes
The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in pediatric Type 2 diabetes patients improves short term time in range glucose control and 3-6 month glycemic…
- Trial name
- IMPaCT2 (NCT04721158)
- Testing
- Continuous glucose monitor
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, High HbA1c Level
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.
- Conditions
- Type 2 Diabetes Mellitus, High HbA1c Level, Inadequate Glycaemic Control
- Trial name
- NCT01392677
- Testing
- dapagliflozin
- Where
- 42 sites in Canada, Czechia and 4 more
- Volunteers
- 311 people
- Sponsor
- AstraZeneca
Diabetes
Multi-arm Intervention Diabetes Adherence Study
The purpose of this study is to compare the effectiveness of two different interventions to improve adherence to diabetes medications among patients with diabetes and poor metabolic control.
- Trial name
- MIDAS (NCT00754741)
- Testing
- Adherence information, Adherence information plus motivational interviewing
- Where
- United States
- Volunteers
- 1,692 people
- Sponsor
- Henry Ford Health System
Diabetes Mellitus, Type 2
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with…
- Trial name
- NCT00968812
- Testing
- Glimepiride, Canagliflozin (JNJ-28431754), Metformin
- Where
- 138 sites in United States, Argentina and 18 more
- Volunteers
- 1,452 people
- Sponsor
- Janssen Research & Development, LLC